http://www.futureprescriber.co.uk Future Prescriber current issue RSS Feed http://www.futureprescriber.co.uk/details/journalArticle/759159/The_promise_of_future_treatments_in_AF_is_it_all_over_for_warfarin_.html Abstract Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley & Sons, Ltd. 2010-07-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/759167/The_promise_of_future_treatments_in_AF_is_it_all_over_for_warfarin_.html Abstract Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley & Sons, Ltd. 2010-07-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589013/New_directions_in_cancer_therapy__HDAC_inhibitors_.html Abstract The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non‐Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve... 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589011/New_directions_in_cancer_therapy__HDAC_inhibitors_.html Abstract The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non‐Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve... 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520589/AntiTNFalpha_drugs__moving_into_the_mainstream_.html Abstract Anti‐TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease‐modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti‐TNF‐alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd. ... 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520591/AntiTNFalpha_drugs__moving_into_the_mainstream_.html Abstract Anti‐TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease‐modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti‐TNF‐alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd. ... 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/303733/Management_of_prostate_cancer_future_treatment_approaches_.html Abstract Prostate cancer is now the most commonly diagnosed cancer in men. This may reflect a true increase in the incidence of the disease, but a component of it is certainly related to increased detection rates due to opportunistic prostate specific antigen (PSA) testing. In this article, Professor Malcolm Mason reviews the current treatment of prostate cancer and considers promising future treatment options, including the... 2009-08-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/303725/Management_of_prostate_cancer_future_treatment_approaches_.html Abstract Prostate cancer is now the most commonly diagnosed cancer in men. This may reflect a true increase in the incidence of the disease, but a component of it is certainly related to increased detection rates due to opportunistic prostate specific antigen (PSA) testing. In this article, Professor Malcolm Mason reviews the current treatment of prostate cancer and considers promising future treatment options, including the... 2009-08-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/186572/Highcost_drugs__the_Welsh_perspective_.html 2009-04-28T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/162179/Tocilizumab__IL6_inhibition_for_the_treatment_of_rheumatoid_arthritis_.html Abstract Affecting approximately 400 000 people in England and Wales,1 rheumatoid arthritis (RA) creates a considerable economic burden. NICE estimates that five years after diagnosis, 40% of RA patients will be incapable of work.1 Some treatment options for RA look to control inflammation in order to rein in the disease. Interleukin‐6 (IL‐6) invokes inflammation via TNF‐α, although the reason for this is unknown. Some researchers are beginning... 2009-02-26T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/121928/Etanercept_a_new_option_in_paediatric_plaque_psoriasis_.html Abstract Psoriasis in children and adolescents can be disfiguring and adversely affect quality of life. A range of treatments are available that can control the condition, but not all patients respond or are able to tolerate the treatments. The anti‐TNF alpha inhibitors are used effectively in adult psoriasis but are not currently licensed for use in children. The anti‐TNF etanercept (Enbrel) has been studied in childhood psoriasis... 2009-01-19T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/119154/Use_of_unlicensed_drugs_what_are_the_issues_.html 2008-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/119141/Can_NICE_do_its_job_.html 2008-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/119132/Treatment_options_in_pulmonary_arterial_hypertension_.html Abstract Pulmonary arterial hypertension (PAH) is a rare, severe and progressive disease characterised by raised pressures in the arteries in the lungs leading to right heart failure and, historically, a median life expectancy of 2.8 years with‐out targeted treatment.1 Pathologically, it is characterised by a thickening of the muscular layer of the arteries, dysfunction of the vessel walls, and abnormal growth of supporting cells such as... 2008-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/119147/Primary_prevention_for_all_.html 2008-07-07T00:00:00Z